gpr4

GPR4 antagonist 1 is a GPR4 antagonist with an IC50 of 189 nM.

GPR40 FFAR1 modulator 1 is a Gq-coupled free fatty acid receptor 1 (GPR40 FFAR1) agonist and allosteric modulator.

GPR40 agonist 1 is an effective new GPR40 agonist (EC50s: 17 nM and 2 nM for rGPR40 and hGPR40).

GPR40 Agonist 2 is a compound that functions as a GPR40 agonist and is utilized in diabetes research.

GPR40 agonist 5 is an orally active GPR40 (G protein-coupled receptor 40) agonist (EC50: 47 nM). gPR40 agonist 5 reduces blood glucose levels and improves glucose tolerance. gPR40 agonist 5 shows adequate control of hyperglycemic state in type 2 diabetic mice.

GPR40 Activator 2 is a highly effective activator of the GPR40 receptor.

GPR40 Activator 1 is a potent activator of GPR40 for the treatment of type 2 diabetes.

GPR40 agonist 6 (Compound 7a) is a potent and selective agonist of free fatty acid receptor 1 (FFAR1 or GPR40) with an EC50 of 0.058 μM against GPR40 [1].

Compound 1, also known as GPR40 agonist 7, is an orally active agonist of the G protein-coupled receptor 40 (GPR40). It effectively enhances the secretion of insulin and GLP-1, exhibiting a hypoglycemic effect in vivo with an ED 50 of 0.58 mg kg [1].

GPR41 agonist-1 is a GPR41 agonist, useful for studying metabolic diseases such as diabetes and obesity.

Chikusetsusaponin IVa (Calenduloside F) is a novel AMPK activator, can induce insulin secretion from βTC3 cells via GPR4 mediated calcium and PKC pathways, may be developed into a new potential for therapeutic agent used in T2DM patients.

AMG 837 sodium salt is a potent GPR40 agonist(EC50=13 nM) with a superior pharmacokinetic profile and robust glucose-dependent stimulation of insulin secretion in rodents. IC50 value: 13 nM (EC50) [1] Target: GPR40 agonist AMG 837 displayed the expected t

NE 52-QQ57 is a selective, orally available antagonist of GPR4 (IC50: 70 nM) with anti-inflammatory activity.